[Mechanism of recombinant human growth hormone accelerating burn wound healing in burn patients].

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To investigate the mechanism of recombinant human growth hormone (rhGH) in acceleration of burn wound healing.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Thirty three severe burn patients were enrolled in this study and randomly divided into rhGH group (n = 18) and placebo control group (n = 15).

How the Study Was Run

The design is described as randomized and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

The serum concentration of GH and IGF-1 were assayed with ELISA method, and the proliferation index (PI) and S-phase fraction (SPF) of wound tissue was analyzed by flow cytometry (FCM).

The expression of PCNA, EGFR and CK was assessed by immunohistochemical stains.

What Was Measured

Topics PubMed links to this paper include Burns, Creatine Kinase, ErbB Receptors, Growth Hormone, Proliferating Cell Nuclear Antigen and Wound Healing.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2000 (Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns), a journal based in China.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.